AR050358A1 - Composiciones capaces de inhibir especies reactivas de oxigeno y carbonilo - Google Patents
Composiciones capaces de inhibir especies reactivas de oxigeno y carboniloInfo
- Publication number
- AR050358A1 AR050358A1 ARP050103078A ARP050103078A AR050358A1 AR 050358 A1 AR050358 A1 AR 050358A1 AR P050103078 A ARP050103078 A AR P050103078A AR P050103078 A ARP050103078 A AR P050103078A AR 050358 A1 AR050358 A1 AR 050358A1
- Authority
- AR
- Argentina
- Prior art keywords
- tetramethylchroman
- hydroxy
- compositions
- piperazine
- ethyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- External Artificial Organs (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se proveen composiciones terapéuticas. Las composiciones incluyen una molécula unica que puede exhibir propiedades secuestrantes y antioxidantes de carbonilo. Esto puede rducir efectivamente la inflamacion, el estrés oxidativo y el estrés de carbonilo, a fin de prevenir y/o tratar la enfermedad cardiovascular y las enfermedades inflamatorias en pacientes con enfermedades renales. Método de preparacion de la composicion; método de tratamiento. Reivindicacion 8: La composicion de la reivindicacion 6, caracterizada porque el derivado de vitamina E se selecciona del grupo que consiste de 2-(6-hidroxi-2,5,7,8-tetrametilcroman-2-il)-1-(aminoxi)etano; N-[2-(6-hidroxi-2,5,7,8-tetrametilcroman-2-il)etil]-N'-(aminoacetil)-piperazina; N- [2-(6-hidroxi-tetrametilcroman-2-il)etil]-N'-(cisteinil)-piperazina; N-[2-(6-hidroxi-tetrametilcroman-2-il)etil]-N'-(penicilamil)-piperazina, derivados de eso, y combinaciones de eso.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/899,194 US7384558B2 (en) | 2004-07-26 | 2004-07-26 | Compositions capable of inhibiting reactive oxygen and carbonyl species |
Publications (1)
Publication Number | Publication Date |
---|---|
AR050358A1 true AR050358A1 (es) | 2006-10-18 |
Family
ID=35134231
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP050103078A AR050358A1 (es) | 2004-07-26 | 2005-07-25 | Composiciones capaces de inhibir especies reactivas de oxigeno y carbonilo |
Country Status (7)
Country | Link |
---|---|
US (1) | US7384558B2 (es) |
EP (1) | EP1771168A1 (es) |
JP (1) | JP2008507580A (es) |
AR (1) | AR050358A1 (es) |
MX (1) | MX2007000742A (es) |
TW (1) | TW200614986A (es) |
WO (1) | WO2006019855A1 (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4004523B1 (ja) * | 2006-04-21 | 2007-11-07 | 株式会社日本トリム | 透析液調製用水およびそれを用いた透析液、透析液の製造方法ならびに透析装置 |
US20080138481A1 (en) * | 2006-12-07 | 2008-06-12 | Chi-Tang Ho | Methods of reducing reactive carbonyl species |
CA2932121A1 (en) * | 2007-11-30 | 2009-06-11 | Newlink Genetics Corporation | Ido inhibitors |
TW201338803A (zh) * | 2012-03-23 | 2013-10-01 | zheng-yi Lin | 用於治療寵物腎衰竭之醫藥組合物 |
JP6255975B2 (ja) | 2012-12-27 | 2018-01-10 | Jnc株式会社 | 液晶組成物、酸化防止剤および液晶表示素子 |
EP3120842A1 (en) | 2015-07-20 | 2017-01-25 | Opterion Health AG | Peritoneal therapeutic fluid |
CN110573196A (zh) * | 2017-03-30 | 2019-12-13 | 日本多宁股份有限公司 | 血液透析用透析液 |
Family Cites Families (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US138501A (en) * | 1873-05-06 | Improvement in molasses-pitchers | ||
US20507A (en) * | 1858-06-08 | Combined umbrella and head-best | ||
US17995A (en) * | 1857-08-11 | Winnowing-mill | ||
US119957A (en) * | 1871-10-17 | Improvement in photographic tents | ||
US65292A (en) * | 1867-05-28 | Improved apparatus for tanning | ||
US4105A (en) * | 1845-07-10 | Fait-mill | ||
US37329A (en) * | 1863-01-06 | Improvement in rammer-connections for revolving fire-arms | ||
DE3010504A1 (de) * | 1980-03-19 | 1981-10-01 | Basf Ag, 6700 Ludwigshafen | Verfahren zur herstellung von 2-hydroxyalkylchromanen |
DE3615473A1 (de) * | 1986-05-07 | 1987-11-12 | Basf Ag | Verfahren zur herstellung von o-substituierten hydroxylaminen |
CA2011899A1 (en) | 1989-03-13 | 1990-09-13 | Masaaki Toda | Benzopyran derivatives |
US5266709A (en) * | 1989-03-13 | 1993-11-30 | Ono Pharmaceutical Co., Ltd. | Benzopyran derivatives |
US5668117A (en) * | 1991-02-22 | 1997-09-16 | Shapiro; Howard K. | Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments |
JPH04308586A (ja) | 1991-04-05 | 1992-10-30 | Ono Pharmaceut Co Ltd | ベンゾピラン誘導体 |
DK0636018T3 (da) * | 1993-01-19 | 1997-12-08 | Baxter Int | Flerkammerbeholder |
US5527272A (en) * | 1994-02-14 | 1996-06-18 | Fresenius Usa, Inc. | Bacteriocidal dialysis collection bag and method |
ATE222766T1 (de) | 1994-07-01 | 2002-09-15 | Baxter Int | Biochemisch isotone peritonealdialyselösungen |
JPH11504316A (ja) * | 1995-04-05 | 1999-04-20 | ザ ピコワー インスティテュート フォア メディカル リサーチ | 進行性グリコシル化終末産物に結合する薬剤及びその使用方法 |
JPH08337590A (ja) | 1995-06-15 | 1996-12-24 | Terumo Corp | 腹膜保護成分およびそれを含有した腹膜透析液 |
US6436969B1 (en) | 1995-09-12 | 2002-08-20 | Kansas University Medical Center Research Institute Inc. | Dialysis solutions and methods |
ZA978002B (en) * | 1996-09-11 | 1998-03-02 | Baxter Int | Containers and methods for storing and admixing medical solutions. |
US6610683B2 (en) * | 1996-09-12 | 2003-08-26 | Idun Pharmaceuticals, Inc. | Treatment of infectious disease using interleukin-1β-converting enzyme (ICE)/CED-3 family inhibitors |
US5925542A (en) * | 1997-05-05 | 1999-07-20 | Incyte Pharmaceuticals, Inc. | Nucleic acid encoding human phosphodiesterase regulatory subunit |
JPH1171273A (ja) | 1997-08-29 | 1999-03-16 | Terumo Corp | 腹膜透析液 |
US6258577B1 (en) * | 1998-07-21 | 2001-07-10 | Gambro, Inc. | Method and apparatus for inactivation of biological contaminants using endogenous alloxazine or isoalloxazine photosensitizers |
US6277337B1 (en) | 1998-07-21 | 2001-08-21 | Gambro, Inc. | Method and apparatus for inactivation of biological contaminants using photosensitizers |
JP3811008B2 (ja) | 1998-08-24 | 2006-08-16 | 黒川 清 | カルボニルストレス状態改善剤、および腹膜透析液 |
US6475434B1 (en) * | 1998-12-07 | 2002-11-05 | Baylor College Of Medicine | Composition and methods for preventing and removing biofilm embedded microorganisms from the surface of medical devices |
AU3512400A (en) * | 1999-03-05 | 2000-09-21 | Kansas University Medical Center | Novel post-amadori inhibitors of advanced glycation reactions |
KR100390630B1 (ko) | 1999-07-02 | 2003-07-07 | 이희발 | 항 산화제를 함유한 복막투석액 |
US6309673B1 (en) * | 1999-09-10 | 2001-10-30 | Baxter International Inc. | Bicarbonate-based solution in two parts for peritoneal dialysis or substitution in continuous renal replacement therapy |
CN100355452C (zh) * | 1999-12-20 | 2007-12-19 | 黑川清 | 羰基应激改良剂 |
US6417235B2 (en) * | 2000-04-14 | 2002-07-09 | University Of Kentucky Research Foundation | Method and use of α-amino-β-mercapto-ethane derivatives as dicarbonyl scavengers for treatment of conditions resulting from protein, lipid, and DNA damage |
JPWO2002047677A1 (ja) | 2000-12-12 | 2004-04-15 | 宮田 敏男 | カルボニルストレスの改善剤 |
SE523153C2 (sv) | 2000-12-28 | 2004-03-30 | Gambro Lundia Ab | Metod för detoxifiering av medicinsk lösning |
US7037895B2 (en) | 2001-03-27 | 2006-05-02 | Medical College Of Ohio | Albumin-based colloid composition and method of use in treating hypovolemia and multiorgan dysfunction |
WO2002094179A2 (en) | 2001-05-23 | 2002-11-28 | J.B. Chemicals & Pharmaceuticals Ltd. | Novel topical microbicidal compositions |
WO2002100455A2 (en) | 2001-06-08 | 2002-12-19 | Baylor College Of Medicine | Use of ozone for the prevention of infection caused by medical devices |
US20030007961A1 (en) * | 2001-06-22 | 2003-01-09 | Wilburn Michael D. | Orthomolecular vitamin E derivatives |
GB0127786D0 (en) | 2001-11-20 | 2002-01-09 | Univ Nottingham | Impregnation of antimicrobial substances |
DE10159245A1 (de) | 2001-12-03 | 2003-06-18 | Degussa | Stabile, saure, wässrige Lösung enthaltend alpha-Liponsäure(-Derivate), Verfahren zu deren Herstellung sowie ihre Verwendung |
US7122210B2 (en) | 2002-01-11 | 2006-10-17 | Baxter International Inc. | Bicarbonate-based solutions for dialysis therapies |
GB0200704D0 (en) | 2002-01-14 | 2002-02-27 | Britannia Pharmaceuticals Ltd | Use of phospholipids in peritoneal dialysis |
US7053059B2 (en) * | 2003-07-25 | 2006-05-30 | Baxter International Inc. | Dialysis solutions with reduced levels of glucose degradation products |
-
2004
- 2004-07-26 US US10/899,194 patent/US7384558B2/en not_active Expired - Fee Related
-
2005
- 2005-06-22 MX MX2007000742A patent/MX2007000742A/es active IP Right Grant
- 2005-06-22 JP JP2007523607A patent/JP2008507580A/ja not_active Withdrawn
- 2005-06-22 EP EP05772632A patent/EP1771168A1/en not_active Withdrawn
- 2005-06-22 WO PCT/US2005/024913 patent/WO2006019855A1/en active Application Filing
- 2005-06-27 TW TW094121394A patent/TW200614986A/zh unknown
- 2005-07-25 AR ARP050103078A patent/AR050358A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
WO2006019855A1 (en) | 2006-02-23 |
US7384558B2 (en) | 2008-06-10 |
MX2007000742A (es) | 2007-03-30 |
TW200614986A (en) | 2006-05-16 |
EP1771168A1 (en) | 2007-04-11 |
JP2008507580A (ja) | 2008-03-13 |
US20060016752A1 (en) | 2006-01-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR050358A1 (es) | Composiciones capaces de inhibir especies reactivas de oxigeno y carbonilo | |
O'Leary et al. | Adaptive plasticity of autophagic proteins to denervation in aging skeletal muscle | |
JP7054691B2 (ja) | 表皮水疱症及び関連する結合組織疾患の治療におけるカンナビノイドの局所製剤の使用 | |
DOP2019000287A (es) | Anticuerpos monoclonales contra el inhibidor de la vía del factor tisular (tfpi) | |
CO6331425A2 (es) | Composiciones que comprenden n-(3,4-difluoro-2-(2-fluoro-4-yodofenilamino)6-metoxifenil)-1-(2,3-dihidroxiproxipropil)ciclopropan-1-sulfamida | |
Vicentini et al. | Evaluation of protective effect of a water-in-oil microemulsion incorporating quercetin against UVB-induced damage in hairless mice skin | |
GT200600096A (es) | Composicion farmaceutica para el tratamiento del cancer | |
EP2925307A1 (en) | Hydroxytyrosol and oleuropein compositions for induction of dna damage, cell death and lsd1 inhibition | |
NO20060977L (no) | Mitokinon-derivater anvendt som mitokondrielle malsokende antioksidanter | |
NO20060978L (no) | Farmasoytiske blandingr for behandling av prematur ejakulasjon ved pulmonal inhalering | |
NO20065079L (no) | Materialer og metoder for behandling av koaguleringssykdommer | |
Ashraf et al. | Endothelium mediated vasorelaxant response of garlic in isolated rat aorta: role of nitric oxide | |
Ranjbar et al. | Cardioprotective effect of resistance training and Crataegus oxyacantha extract on ischemia reperfusion–induced oxidative stress in diabetic rats | |
AR109263A2 (es) | Composición que comprende moxidectina | |
Baranowska-Kuczko et al. | Endothelium-dependent mechanisms of the vasodilatory effect of the endocannabinoid, anandamide, in the rat pulmonary artery | |
AR048336A1 (es) | Hidrocloruro de (4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il)-(4-bromo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos | |
EA201071043A1 (ru) | Новые производные 1-бензил-3-гидроксиметилиндазола и их применение при лечении заболеваний, обусловленных экспрессией mcp-1 и cx3cr1 | |
ATE451922T1 (de) | Verwendung von thiazolidinon-derivaten zur behandlung von festen tumoren | |
EA200702030A1 (ru) | Производные альфа-кетоамидов в качестве ингибиторов цистеинпротеаз | |
BRPI0414334A (pt) | withanamida isolada e purificada, composto isolado e purificado, método para tratamento de uma doença in vivo em um mamìfero, método para provisão de oxidação em uma composição necessitada da mesma, composição, composição para uso como produto farmacêutico, método para tratamento de uma doença selecionada do grupo que conpreende a doença de alzheimer, obesidade, dores de cabeça de enxaqueca, e depressão, em um paciente, e método para tratamento antioxidante de um mamìfero in vivo | |
AR064543A1 (es) | Uso de derivados de mononitrato de dianhidrohexita como agentes para el tratamiento de trastornos intestinales | |
ATE424732T1 (de) | Zubereitungen enthaltend mehrfach ungesättigte phospholipide, monoterpene und tryptophan und/oder phytol-derivate | |
CA3153877A1 (en) | Curcuminoid composition and its therapeutic potential in managing lung fibrosis | |
Li et al. | L-Arginine and allopurinol supplementation attenuates inflammatory mediators in human osteoblasts–osteoarthritis cells | |
AR026022A1 (es) | Metodo para el tratamiento de la obesidad |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |